Despite advances in hepatitis C therapy and better knowledge of viral/host factors related to disease progression, hepatitis C virus (HCV) remains the leading cause of chronic liver disease, causing progression to end-stage liver disease (ESLD) as well as the development of hepatocellular carcinoma. In this paper a mathematical model for assessing the impact of antiviral therapy, abstinence and relapse on the transmission dynamics of HCV is formulated and analyzed. A threshold quantity known as the reproductive number has been computed, and the stability of the steady states has been investigated. The dynamical analysis reveals that the model has globally asymptotically stable steady states. The impacts of antiviral therapy, abstinence and relapse on the transmission dynamics of HCV are discussed through the basic reproductive number and numerical simulations.
AsselahT. Hepatitis C: Viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int2010; 30: 1259–1269.
2.
SorianoVPetersMGZeuzemS. New therapies for hepatitis C virus infection. Clin Infect Dis2009; 48: 313–320.
3.
DemirtürkNDemirdalTToprakD. Hepatitis B and C virus in west-central Turkey: Seroprevalence in healthy individuals admitted to a university hospital for routine health checks. Turk J Gastroenterol2006; 17: 267–272.
4.
HadziyannisSJ. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med2004; 140: 346–355.
5.
KamalSM. Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response. Gastroenterol2006; 130: 632–638.
6.
GrebelyJ. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend2008; 93: 141–147.
7.
LettmeierB. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol2008; 49: 528–536.
8.
MargaretHSacks-DavisRGoldJ. Hepatitis C treatment for injection drug users: A review of the available evidence. Clin Infect Dis2009; 49: 561–573.
9.
MehtaS. Limited uptake of hepatitis C treatment among injection drug users. J Commun Health2008; 33: 126–133.
10.
Australian Government Department of Health and Aged Care. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners. Canberra: Department of Health and Aged Care and Medicare Australia, Pharmaceutical Benefits Scheme, 2001.
11.
ReimerJ. Guidelines for the treatment of hepatitis C virus infection in injection drug users: Status quo in the European Union countries. Clin Infect Dis2005; 40(Suppl 5): S373–S378.
12.
BhunuCPMushayabasaS. Assessing the effects of intravenous drug use on Hepatitis C transmission dynamics. J Biol Syst2011; 19: 474–460.
13.
MushayabasaSBhunuCP. Epidemiological consequences of non-compliance to HCV therapy among IDUs. Int J Res Rev Appl Sci2011; 8: 288–295.
14.
MartinKNVickermanPHickmanM. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol2011; 274: 58–66.
15.
MushayabasaSBhunuCPSmithRJ. Assessing the impact of educational campaigns on controlling HCV among women prisoners. Commun Nonlin Sci Numer Simul2012; 17: 1714–1724.
16.
ZhangSZhouY. Dynamics and applications of an epidemiological model for hepatitis C. Math Comput Model2012; 56: 36–42.
17.
HejblumG. Modelers’ perception of mathematical modelling in epidemiology: A web-based survey. PLoS ONE2011; 6(1): e16531. doi:10.1371/journal.pone.001653.
18.
HethcoteHW. The mathematics of infectious diseases. SIAM Rev2000; 42: 599–653.
19.
Van den DriesschePWatmoughJ. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math Biosci2002; 180: 29–48.
20.
BlowerSMDowlatabadiH. Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example. Int Stat Rev1994; 2: 229–243.
21.
MicallefJMKaldorJMDoreGJ. Spontaneous viral clearance following hepatitis C infection: A systematic review of longitudinal studies. J Viral Hepat2006; 13: 34–41.
22.
EdlinRB. Prevention and treatment of hepatitis C in injection drug users. Hepat2002; 36: S210–S219.
23.
Castillo-ChavezCFengZHuangW. On the computation of and its role on global stability. In: Castillo-ChavezC. (eds) Mathematical approaches for emerging and reemerging infectious diseases: An introduction [The IMA Volumes in Mathematics and its Applications, Vol. 125], 229–250. New York: Springer.
24.
Castillo-ChavezCSongB. Dynamical models of tuberculosis and their applications. Math Biosci Eng2004; 1: 361–404.
25.
CarrJ. Applications of centre manifold theory. New York, NY: Springer, 1981.
26.
LiYMMuldowneyJS. A geometric approach to global stability problems. SIAM J Math Anal1996; 27: 1070–1083.
27.
CoppelWA. Stability and asymptotic behavior of differential equations. Boston, MA: D.C. Health and Company, 1965.
